Ilian Iliev Net Worth

Ilian Iliev biography

Dr. Ilian Iliev serves as Director of the Company. Dr. Iliev joined PDS’s Board of Directors in April 2020. Dr. Iliev, has served as a Managing Director of EMV Capital since September 2018, a London-based investor in B2B companies in the healthcare, energy and industrial sectors. Dr. Iliev spun EMV Capital out of EcoMachines Ventures, which he co-founded in March 2013. From September 2006 through January 2013, Dr. Iliev served as the Chief Executive Officer and co-founder of CambridgeIP Ltd, a technology business intelligence provider in the United Kingdom and has served as a Founder Director of CambridgeIP Ltd since February 2013. Dr. Iliev also currently serves as a Non-Executive Director of NetScientific plc, a transatlantic healthcare IP commercialization group that funds and develops companies that are working to significantly improve the health and well-being of people with chronic diseases. Dr. Iliev also serves on the Board of Directors of Sofant Technologies, Pointgrab, Q-Bot, Vortex Biosciences and Wanda Health. Dr. Iliev holds a Ph.D. from Cambridge University’s Judge Business School, focused on Venture Capital business models in emerging economies. Dr. Iliev also received a Master of Commerce in Economics, and Bachelor of Arts in Politics, Economics and International Relations from the University of Witwatersrand, South Africa.

What's Ilian Iliev's mailing address?

Ilian's mailing address filed with the SEC is C/O PDS BIOTECHNOLOGY CORPORATION, 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540.

Insiders trading at PDS Biotechnology

Over the last 5 years, insiders at PDS Biotechnology have traded over 0$ worth of PDS Biotechnology stock and bought 54,275 units worth 476,657$ . The most active insiders traders include Gregory Gene Freitag、James J Loughlin、Kamil Ali Jackson. On average, PDS Biotechnology executives and independent directors trade stock every 67 days with the average trade being worth of 126,706$. The most recent stock trade was executed by Frank Bedu Addo on 2 December 2022, trading 219,535 units of PDSB stock currently worth 1,442,345$.

What does PDS Biotechnology do?

pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati

PDS Biotechnology executives and stock owners

PDS Biotechnology executives and other stock owners filed with the SEC include:

• Frank Bedu-Addo,
  President, Chief Executive Officer, Director
• Dr. Frank K. Bedu-Addo Ph.D.,
  Pres, CEO & Director
• Gregory Conn,
  Chief Scientific Officer
• Lauren V. Wood M.D.,
  Chief Medical Officer
• Dr. Gregory L. Conn,
  Chief Scientific Officer
• Gregory Freitag,
  Independent Director
• DeLyle Bloomquist,
  Independent Director
• Stephen Glover,
  Independent Chairman of the Board
• Richard Sykes,
  Independent Director
• Otis Brawley,
  Director
• Deanne Randolph,
  Investor Relations
• Kamil Ali-Jackson,
  Independent Director
• Ilian Iliev,
  Director
• Lauren Wood,
  Chief Medical Officer
• Michael King,
  Interim Chief Financial Officer
• Janetta Trochimiuk,
  Controller
• Dr. Mark Baxter Ph.D.,
  Sr. VP of Global Quality
• Hillary Yegen,
  VP of Legal
• Dr. Joe J. Dervan,
  VP of R&D
• Matthew C. Hill CPA,
  CFO & Principal Accounting Officer
• Matthew C Hill,
  Chief Financial Officer
• James J Loughlin,
  Director
• Voorhees Seth Van,
  Chief Financial Officer
• Lars Boesgaard,
  Chief Financial Officer
• Spencer D. Brown,
  Senior VP, General Counsel
• Kirk V. Shepard,
  Chief Medical Officer
• Stephan Toutain,
  Chief Operations Officer